343 related articles for article (PubMed ID: 26184955)
1. Association of the ABCB1 C3435T polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis : A meta-analysis.
Lee YH; Bae SC; Song GG
Z Rheumatol; 2016 Sep; 75(7):707-15. PubMed ID: 26184955
[TBL] [Abstract][Full Text] [Related]
2. Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.
Lee YH; Bae SC
Rheumatol Int; 2016 Nov; 36(11):1591-1599. PubMed ID: 27379764
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.
Takatori R; Takahashi KA; Tokunaga D; Hojo T; Fujioka M; Asano T; Hirata T; Kawahito Y; Satomi Y; Nishino H; Tanaka T; Hirota Y; Kubo T
Clin Exp Rheumatol; 2006; 24(5):546-54. PubMed ID: 17181924
[TBL] [Abstract][Full Text] [Related]
4. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.
Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y
Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis.
Plaza-Plaza JC; Aguilera M; Cañadas-Garre M; Chemello C; González-Utrilla A; Faus Dader MJ; Calleja MA
OMICS; 2012 Nov; 16(11):589-95. PubMed ID: 23095111
[TBL] [Abstract][Full Text] [Related]
6. Association between
He X; Sun M; Liang S; Li M; Li L; Yang Y
Pharmacogenomics; 2019 Apr; 20(5):381-392. PubMed ID: 30983549
[No Abstract] [Full Text] [Related]
7. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients.
Samara SA; Irshaid YM; Mustafa KN
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):746-55. PubMed ID: 25074866
[TBL] [Abstract][Full Text] [Related]
8. ABCB1 C3435T polymorphism and the risk of coronary heart disease: a meta-analysis.
Jin Y; Wang Q; Wang G; Zhang X; Yan B; Hu W
Genet Test Mol Biomarkers; 2014 Mar; 18(3):164-73. PubMed ID: 24328528
[TBL] [Abstract][Full Text] [Related]
9. Can we predict unresponsiveness to methotrexate in rheumatoid arthritis? A pharmacogenetic study.
Melikoglu MA; Balkan E
Inflammopharmacology; 2022 Feb; 30(1):193-197. PubMed ID: 35043269
[TBL] [Abstract][Full Text] [Related]
10. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population.
Cáliz R; del Amo J; Balsa A; Blanco F; Silva L; Sanmarti R; Martínez FG; Collado MD; Ramirez Mdel C; Tejedor D; Artieda M; Pascual-Salcedo D; Oreiro N; Andreu JL; Graell E; Simon L; Martínez A; Mulero J
Scand J Rheumatol; 2012 Feb; 41(1):10-4. PubMed ID: 22044028
[TBL] [Abstract][Full Text] [Related]
11. Association of transforming growth factor-β1 T869C, G915C, and C509T gene polymorphisms with rheumatoid arthritis risk.
Zhou TB; Zhao HL; Fang SL; Drummen GP
J Recept Signal Transduct Res; 2014 Dec; 34(6):469-75. PubMed ID: 24840097
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of the association between the ATIC 347 C/G polymorphism and methotrexate responsiveness and toxicity in rheumatoid arthritis.
Lee YH; Song GG
Semin Arthritis Rheum; 2024 Feb; 64():152337. PubMed ID: 38071832
[TBL] [Abstract][Full Text] [Related]
13. Associations between the interleukin-6 rs1800795 G/C and interleukin-6 receptor rs12083537 A/G polymorphisms and response to disease-modifying antirheumatic drugs in rheumatoid arthritis: A meta-analysis.
Lee YH; Song GG
Int Immunopharmacol; 2022 Nov; 112():109184. PubMed ID: 36058033
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.
Choy EH; Smith C; Doré CJ; Scott DL
Rheumatology (Oxford); 2005 Nov; 44(11):1414-21. PubMed ID: 16030080
[TBL] [Abstract][Full Text] [Related]
15. TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis.
Bae SC; Lee YH
Z Rheumatol; 2018 Nov; 77(9):824-832. PubMed ID: 29380036
[TBL] [Abstract][Full Text] [Related]
16. ABCB1-C3435T polymorphism and breast cancer risk: a case-control study and a meta-analysis.
Sharif A; Kheirkhah D; Reza Sharif M; Karimian M; Karimian Z
J BUON; 2016; 21(6):1433-1441. PubMed ID: 28039704
[TBL] [Abstract][Full Text] [Related]
17. Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis.
Chen Y; Zou K; Sun J; Yang Y; Liu G
Pharmacogenomics; 2017 Jan; 18(2):175-195. PubMed ID: 27992285
[TBL] [Abstract][Full Text] [Related]
18. Association of IL17A and IL17F genes with rheumatoid arthritis disease and the impact of genetic polymorphisms on response to treatment.
Marwa OS; Kalthoum T; Wajih K; Kamel H
Immunol Lett; 2017 Mar; 183():24-36. PubMed ID: 28143790
[TBL] [Abstract][Full Text] [Related]
19. Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.
Xia Z; Lyu J; Hou N; Song L; Li X; Liu H
Z Rheumatol; 2016 Oct; 75(8):828-833. PubMed ID: 26508503
[TBL] [Abstract][Full Text] [Related]
20. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ
Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
